Sci Immun: Geneva and Harvard University found a new immunotherapy without side effects

In recent years, immunotherapy has completely changed the field of cancer treatment
.
However, inflammatory reactions in healthy tissues often trigger side effects, which can be severe and lead to permanent discontinuation of treatment

.

immunity

Recently, scientists from the University of Geneva, Switzerland (UNIGE) and Harvard University Medical School in the United States have successfully determined the difference between harmful immune responses and those directed at tumor cells .
Although the immune mechanisms are similar, the cell populations involved are different.
Different
.
Currently, this publication in Science Immunology makes it possible for us to devise more targeted, more effective and less dangerous treatments for cancer patients

.

The difference between harmful immune responses and those directed at tumor cells has been successfully determined .

Based on the large-scale stimulation of the patient's immune system, immunotherapy has saved many lives

.

Fund tumor immunity

Scientists used liver biopsy samples from patients suffering from this toxic reaction under CHUV and HUG treatment to study the cellular and molecular mechanisms at work to reveal similarities and dissimilarities

.

Similar response but different cells

Similar response but different cells Similar response but different cells

In the toxic response associated with immunotherapy, two types of immune cells--macrophages and neutrophils--seem to be responsible for attacking healthy tissues, but are not involved in killing cancer cells
.
In contrast, another cell type--dendritic cell populations--does not participate in attacking healthy tissues, but is essential for eliminating cancer cells

.

In the toxic response associated with immunotherapy, two types of immune cells--macrophages and neutrophils--seem to be responsible for attacking healthy tissues, but are not involved in killing cancer cells
.

Yellow: Liver macrophages or Kupffer cells, which secrete IL-12 protein, leading to adverse effects of immunotherapy

.

Yellow: Liver macrophages or Kupffer cells, which secrete IL-12 protein, leading to adverse effects of immunotherapy

Neutralizes neutrophils to achieve double benefits

Neutralize neutrophils to achieve dual benefits Neutralize neutrophils to achieve dual benefits

When macrophages are activated by drugs, they produce inflammatory proteins
.
These in turn activate neutrophils, which perform toxic reactions

.
"Mikaël Pittet said: "This opens up the possibility of limiting the side effects of immunotherapy by manipulating neutrophils
.

Subsequently, the research team confirmed their findings by studying the immune response of mice.
The cell activity of these mice is regulated by genetic tools
.
They can identify a loophole that can be exploited to eliminate these side effects
.

Toxicity affects different organs

Toxicity affects different organs

In fact, neutrophils produce some factors that are important for the development of toxicity, including TNF-α, which may be a therapeutic target
.
TNF-α inhibitors have been used to regulate the immune response of patients with arthritis, and may also be used in cancer treatment to suppress the toxic effects of neutrophils during immunotherapy
.
"In addition, inhibiting neutrophils may be a more effective way to fight cancer: in addition to triggering toxic reactions, some of these cells also promote tumor growth
.
Therefore, by trying to control them, we can have a double beneficial effect: overcoming health Tissue toxicity and limit the growth of cancer cells ", concludes Mikaël Pittet
.

Neutrophils produce some factors that are important for the development of toxicity, including TNF-α, which may be a therapeutic target
.
TNF-α inhibitors have been used to regulate the immune response of patients with arthritis, and may also be used in cancer treatment to suppress the toxic effects of neutrophils during immunotherapy
.
Neutrophils produce some factors that are important for the development of toxicity, including TNF-α, which may be a therapeutic target
.
TNF-α inhibitors have been used to regulate the immune response of patients with arthritis, and may also be used in cancer treatment to suppress the toxic effects of neutrophils during immunotherapy
.
Inhibiting neutrophils may be a more effective way to fight cancer: in addition to triggering a toxic response, some of these cells also promote tumor growth
.
Therefore, by trying to control them, we can have a double beneficial effect: overcoming the toxicity of healthy tissues and limiting the growth of cancer cells.
Inhibition of neutrophils may be a more effective way to fight cancer: in addition to triggering toxic reactions, among them Some cells also promote tumor growth
.
Therefore, by trying to control them, we can have a double beneficial effect: overcoming the toxicity of healthy tissues and limiting the growth of cancer cells

Original source:

Marie Siwicki et al.
Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy.
Science Immunology.
DOI: 10.
1126/sciimmunol.
abi7083

DOI: 10.
1126/sciimmunol.
abi7083

 

Leave a message here